Markets
Will Linear Health Sciences' Orchid SRV be launched in Japan by July 22, 2026?
Yes0%No0%
Loading...
About this market
This market resolves to Yes if Linear Health Sciences and NIPRO CORPORATION launch the Orchid Safety Release Valve (SRV) in the Japanese market on or before July 22, 2026, as per their announcement. The launch must involve public confirmation of product availability in Japan or sales starting by the specified date, confirmed through media reports or an official press release.
Rules
- Market closes at 7/22/2026.
- Logic weighted resolution applies.
Other open markets in Health
Will the NICE-recommended non-invasive tests for endometriosis be implemented in NHS pilot studies by August 31, 2026?
This market resolves to Yes if it is confirmed that the National Health Service (NHS) has begun pilot studies implementing the non-invasive tests for endometriosis recommended by NICE (National Institute for Health and Care Excellence) by August 31, 2026. Public confirmation may come from NHS press releases, reputable UK health media outlets, or official NICE/NHS communications.
Will NICE recommend at least one additional non-invasive diagnostic test for endometriosis by August 31, 2026?
This market resolves to Yes if the UK’s National Institute for Health and Care Excellence (NICE) announces an official recommendation for at least one new non-invasive diagnostic test for endometriosis by August 31, 2026. The resolution will be based on verifiable public announcements or publications by NICE.
Will Utah's AI prescription refill program face state-level regulatory changes by August 31, 2026?
This market resolves to Yes if any new state-level regulations specific to Utah's AI-driven prescription refill pilot program are officially enacted by August 31, 2026. This includes legislation, healthcare board policies, or executive actions aimed explicitly at modifying, expanding, or restricting the program. Public announcements or documented evidence of such changes will determine resolution.
Will the UK government announce updated guidance for managing polycystic ovary syndrome (PCOS) by August 31, 2026?
This market resolves to Yes if the UK government, or the National Institute for Health and Care Excellence (NICE), officially announces updated guidance explicitly concerning the management of polycystic ovary syndrome (PCOS) by August 31, 2026. If no such announcement is made by that date, the market resolves to No. This market was prompted by *The Pharmaceutical Journal* reporting on the establishment of the first UK guidance for polyendocrine metabolic ovarian syndrome.
Will the U.S. death rate remain at a record low in 2026 according to CDC data released by August 31, 2026?
This market resolves to Yes if the CDC reports, by August 31, 2026, that the U.S. death rate for 2026 remains at a record low as described in its provisional data release for the year. This will be based on official CDC death statistics or provisional updates publicly released by that date.
Will the U.S. CDC officially recommend reclassifying Grade Group 1 prostate cancer as a precancerous condition by August 31, 2026?
This market resolves to Yes if the Centers for Disease Control and Prevention (CDC) makes an official recommendation, announcement, or guideline by August 31, 2026, advocating for the reclassification of Grade Group 1 prostate cancer (the earliest and lowest-risk form of the disease) as a precancerous condition. Any such confirmation must be made publicly on the CDC's website, press releases, or official communications. If no such announcement is made by August 31, 2026, this market resolves to No.